Low HDL predicts differential blood pressure effects from two weight-loss approaches: a secondary analysis of blood pressure from a randomized, clinical weight-loss trial

Diabetes Obes Metab. 2012 Apr;14(4):375-8. doi: 10.1111/j.1463-1326.2011.01531.x. Epub 2011 Dec 27.

Abstract

Examining predictors of blood-pressure (BP) response to weight-loss diets might provide insight into mechanisms and help guide clinical care. We examined whether certain baseline patient characteristics (e.g. diet, medical history and laboratory tests) predicted BP response to two weight-loss diet approaches that differ in macronutrient content. One hundred and forty-six overweight adult outpatients were randomized to either a low-carbohydrate diet (N = 72) or orlistat plus a low-fat diet (N = 74) for 48 weeks. Predictors of BP reduction were evaluated using a structured approach and random effects regression models. Participants were 56% African-American, 72% male and 53 (±10) years-old. Of the variables considered, low baseline high-density lipoprotein (HDL) predicted greater reduction in BP in those patients who received the low-carbohydrate diet (p = 0.03 for systolic BP; p = 0.03 for diastolic BP and p = 0.02 for mean arterial pressure). A low HDL level may identify patients who will have greater BP improvement on a low-carbohydrate diet.

Publication types

  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-Obesity Agents / administration & dosage
  • Anti-Obesity Agents / therapeutic use*
  • Blood Pressure* / drug effects
  • Diet, Carbohydrate-Restricted*
  • Diet, Fat-Restricted*
  • Female
  • Humans
  • Lactones / administration & dosage
  • Lactones / therapeutic use*
  • Lipoproteins, HDL / blood*
  • Male
  • Middle Aged
  • Obesity / blood
  • Obesity / diet therapy*
  • Obesity / drug therapy*
  • Orlistat
  • Weight Loss* / drug effects
  • Young Adult

Substances

  • Anti-Obesity Agents
  • Lactones
  • Lipoproteins, HDL
  • Orlistat